News

Embody, Inc. Announces 510(k) Clearances for TAPESTRY® RC for Rotator Cuff Repair

Embody, Inc., a privately-held medical device company focused on soft tissue healing, announced that it has received 510(k) clearances from the Food and Drug Administration (FDA) for its TAPESTRY RC System for the treatment of rotator cuff disease. Uniquely designed for arthroscopic procedures, TAPESTRY RC System combines the healing benefits of the biointegrative collagen TAPESTRY implant with streamlined delivery and fully bioabsorbable anchor fixation.

In 2021, there were an estimated 670,000 rotator cuff repairs in the United States.1 The goal of rotator cuff surgery is to repair the damaged tendon and restore mobility for patients. However, failure can occur due to inadequate healing of the soft tissue, resulting in pain, loss of function and costly reoperations.

“We believe TAPESTRY RC sets a new standard in arthroscopic rotator cuff surgery,” said Jeff Conroy, Chief Executive Officer of Embody. “Building on the clinical utility of TAPESTRY, now in a streamlined, all-in-one solution for arthroscopic rotator cuff surgery.”

The novel design of the TAPESTRY RC System combines an arthroscopic introducer pre-loaded with the TAPESTRY biointegrative collagen implant and the first fully bioabsorbable fixation anchors FDA cleared for use for fixation in both tendon and bone in an easy-to-use, pre-loaded anchor inserter.

“There remains an important clinical need to further improve upon the current healing rates in the treatment of rotator cuff disease,” said Nicholas Sgaglione, MD, senior vice president and executive director of Northwell Health Orthopaedic Institute and Chair and Professor of orthopedics surgery at Northwell Health. “Embody’s TAPESTRY RC System allows for efficient and versatile delivery in a fully bioabsorbable solution to biologic augmentation of the rotator cuff in arthroscopic procedures.”

“Historical focus has been on the mechanical repair of tendon and ligaments, not the biologic augmentation,” said Dr. Wasik Ashraf, Director of Sport Medicine at St. Luke’s Cornwall Hospital. “TAPESTRY has enabled me to bring the power of biostimulative collagen to improve healing of my patients, now in a quick and easy solution to address rotator cuff disease.”

The company is planning to extend its current post market clinical studies in shoulder arthroplasty, foot and ankle, and gluteus medius repair to further include arthroscopic rotator cuff repair.

Recent News

11/18/2026

GeneDx Announces Leadership Transition

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that …

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …